Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested
Executive Summary
The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.
You may also be interested in...
180-Day Exclusivity Changes Pushed In Biden’s Budget Proposal
The legislative proposal would make first-filer exclusivity function similar to the competitive generic therapy program, allowing additional approvals if the commercial launch is delayed.
180-Day Exclusivity Changes Pushed In Biden’s Budget Proposal
The legislative proposal would make first-filer exclusivity function similar to the competitive generic therapy program, allowing additional approvals if the commercial launch is delayed.
Year Of IP: From The TRIPS Waiver Proposal To The Moderna-NIH Patent Tussle
Intellectual property became front page news in 2021 as the pandemic ignited a debate on the role of patents in accessing COVID-19 vaccines and therapeutics. 2022 will see a decision on the TRIPS waiver, a new USPTO director, and action on a pending march-in petition.